Literature DB >> 8856833

The discriminative stimulus effects of tripelennamine in humans.

C E Johanson1, S Evans, J Henningfield.   

Abstract

Twenty volunteers were trained to discriminate between 75 mg tripelennamine (TP) and placebo. During the first four sessions, the drugs were identified prior to ingestion by letter code. During the next six sessions, the procedure was the same except the capsules were not identified. At the end of the 3-h session, participants indicated which capsule they believed they received using the letter codes. When correct, they received a monetary bonus. If they were correct on five sessions, they entered the third phase which had ten additional training and 12 test sessions. During tests, participants received capsules that contained other drugs, including diphenhydramine (50 and 75 mg), chlorpheniramine (4 and 6 mg), diazepam (5 and 10 mg), d-amphetamine (5 and 10 mg), as well as tripelennamine (25, 50 and 75 mg) and placebo. Thirteen participants learned the discrimination and nine entered the third phase. Except for placebo, most participants identified the test compounds as TP and labeled them as sedatives. TP produced significant changes on several subjective and physiological measures. The test compounds produced varied effects which were neither clearly dose-related nor related to the identification as TP or placebo. These results indicate that tripelennamine can function as a discriminative stimulus, but with little evidence of pharmacological specificity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8856833     DOI: 10.1007/bf02246349

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  23 in total

1.  Trends in drug discrimination research analysed with a cross-indexed bibliography, 1984-1987.

Authors:  I P Stolerman; F Rasul; P J Shine
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  The discriminative stimulus and subjective effects of d-amphetamine, phenmetrazine and fenfluramine in humans.

Authors:  L D Chait; E H Uhlenhuth; C E Johanson
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 3.  Relationship between the discriminative stimulus properties and subjective effects of drugs.

Authors:  C R Schuster; C E Johanson
Journal:  Psychopharmacol Ser       Date:  1988

4.  Some behavioral effects of histamine H1 antagonists in squirrel monkeys.

Authors:  J Bergman; R D Spealman
Journal:  J Pharmacol Exp Ther       Date:  1986-10       Impact factor: 4.030

5.  Placebo-effects contribute to differences in the acquisition of drug discrimination by humans: a retrospective analysis.

Authors:  J.B. Kamien; W.K. Bickel; A.H. Oliveto; S.T. Higgins; J.R. Hughes; A.T. Richards; G.J. Badger
Journal:  Behav Pharmacol       Date:  1995-03       Impact factor: 2.293

6.  The discriminative stimulus effects of histamine H(1)-antagonists in pigeons.

Authors:  S.M. Evans; J.P. Zacny; W.L. Woolverton; C.E. Johanson
Journal:  Behav Pharmacol       Date:  1991-12       Impact factor: 2.293

7.  Reinforcing and subjective effects of oral tripelennamine in normal human volunteers.

Authors:  K.N. Stern; L.D. Chait; C.E. Johanson
Journal:  Behav Pharmacol       Date:  1989       Impact factor: 2.293

8.  Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamine.

Authors:  A Barnett; L C Iorio; W Kreutner; S Tozzi; H S Ahn; A Gulbenkian
Journal:  Agents Actions       Date:  1984-06

9.  The discriminative stimulus and subjective effects of d-amphetamine in humans.

Authors:  L D Chait; E H Uhlenhuth; C E Johanson
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

10.  Opioid drug discrimination in humans: stability, specificity and relation to self-reported drug effect.

Authors:  W K Bickel; G E Bigelow; K L Preston; I A Liebson
Journal:  J Pharmacol Exp Ther       Date:  1989-12       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.